Karen Walker - Feb 7, 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
Chief Technology Officer
Signature
By: /s/ Ryan Jones, as Attorney-in-Fact
Stock symbol
KYTX
Transactions as of
Feb 7, 2024
Transactions value $
$0
Form type
3
Date filed
2/7/2024, 09:57 PM
Next filing
Jun 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding KYTX Stock Option (Right to Buy) Feb 7, 2024 Common Stock 92.3K $4.42 Direct F1
holding KYTX Stock Option (Right to Buy) Feb 7, 2024 Common Stock 1.1K $4.33 Direct F2
holding KYTX Stock Option (Right to Buy) Feb 7, 2024 Common Stock 110K $4.83 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the original number of shares subject to the option vested on September 13, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F2 25% of the original number of shares subject to the option shall vest on July 1, 2024, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the original number of shares subject to the option shall vest on January 1, 2025, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney